Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 261

1.

Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.

Solomon H, Sharon M, Rotter V.

Cell Death Differ. 2014 Sep;21(9):1347-9. doi: 10.1038/cdd.2014.99. No abstract available.

PMID:
25109594
[PubMed - in process]
2.

Endothelial Matrix Assembly during Capillary Morphogenesis: Insights from Chimeric TagRFP-Fibronectin Matrix.

Chang F, Lemmon CA, Nilaratanakul V, Rotter V, Romer L.

J Histochem Cytochem. 2014 Jul 25. pii: 0022155414547419. [Epub ahead of print]

PMID:
25063001
[PubMed - as supplied by publisher]
3.

Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.

Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, Chau G, Tashakori M, Wasylishen AR, Ju Z, Solomon H, Rotter V, Liu B, El-Naggar AK, Donehower LA, Martinez LA, Lozano G.

Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11145-50. doi: 10.1073/pnas.1404139111. Epub 2014 Jul 14.

PMID:
25024203
[PubMed - in process]
4.

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.

Shetzer Y, Kagan S, Koifman G, Sarig R, Kogan-Sakin I, Charni M, Kaufman T, Zapatka M, Molchadsky A, Rivlin N, Dinowitz N, Levin S, Landan G, Goldstein I, Goldfinger N, Pe'er D, Radlwimmer B, Lichter P, Rotter V, Aloni-Grinstein R.

Cell Death Differ. 2014 Sep;21(9):1419-31. doi: 10.1038/cdd.2014.57. Epub 2014 May 16.

PMID:
24832469
[PubMed - in process]
5.

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

Rivlin N, Katz S, Doody M, Sheffer M, Horesh S, Molchadsky A, Koifman G, Shetzer Y, Goldfinger N, Rotter V, Geiger T.

Proc Natl Acad Sci U S A. 2014 May 13;111(19):7006-11. doi: 10.1073/pnas.1320428111. Epub 2014 Apr 28.

PMID:
24778235
[PubMed - indexed for MEDLINE]
6.

The paradigm of mutant p53-expressing cancer stem cells and drug resistance.

Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V.

Carcinogenesis. 2014 Jun;35(6):1196-208. doi: 10.1093/carcin/bgu073. Epub 2014 Mar 21. Review.

PMID:
24658181
[PubMed - indexed for MEDLINE]
7.

The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.

Leibovich-Rivkin T, Liubomirski Y, Meshel T, Abashidze A, Brisker D, Solomon H, Rotter V, Weil M, Ben-Baruch A.

BMC Cancer. 2014 Mar 6;14:158. doi: 10.1186/1471-2407-14-158.

PMID:
24598028
[PubMed - in process]
Free PMC Article
8.

p53: the barrier to cancer stem cell formation.

Aloni-Grinstein R, Shetzer Y, Kaufman T, Rotter V.

FEBS Lett. 2014 Aug 19;588(16):2580-9. doi: 10.1016/j.febslet.2014.02.011. Epub 2014 Feb 19.

PMID:
24560790
[PubMed - indexed for MEDLINE]
9.

p53 orchestrates between normal differentiation and cancer.

Rivlin N, Koifman G, Rotter V.

Semin Cancer Biol. 2014 Jan 7. pii: S1044-579X(14)00003-0. doi: 10.1016/j.semcancer.2013.12.006. [Epub ahead of print]

PMID:
24406212
[PubMed - as supplied by publisher]
10.

p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production.

Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V.

Cancer Metab. 2013 Feb 4;1(1):9. doi: 10.1186/2049-3002-1-9.

PMID:
24280180
[PubMed]
11.

Data availability and the need for research to localize, quantify and recycle critical metals in information technology, telecommunication and consumer equipment.

Chancerel P, Rotter VS, Ueberschaar M, Marwede M, Nissen NF, Lang KD.

Waste Manag Res. 2013 Oct;31(10 Suppl):3-16. doi: 10.1177/0734242X13499814.

PMID:
24068305
[PubMed - indexed for MEDLINE]
12.

'Cancer associated fibroblasts'--more than meets the eye.

Madar S, Goldstein I, Rotter V.

Trends Mol Med. 2013 Aug;19(8):447-53. doi: 10.1016/j.molmed.2013.05.004. Epub 2013 Jun 13. Review.

PMID:
23769623
[PubMed - indexed for MEDLINE]
13.

Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, Harpaz N, Itzkowitz S, Harris CC, Rotter V, Gorgoulis VG, Oren M.

Cancer Cell. 2013 May 13;23(5):634-46. doi: 10.1016/j.ccr.2013.03.022. Erratum in: Cancer Cell. 2013 Aug 12;24(2):272. Rozenfeld, Nitzan [corrected to Rosenfeld, Nitzan].

PMID:
23680148
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model.

Olsen JR, Oyan AM, Rostad K, Hellem MR, Liu J, Li L, Micklem DR, Haugen H, Lorens JB, Rotter V, Ke XS, Lin B, Kalland KH.

PLoS One. 2013 May 1;8(5):e62547. doi: 10.1371/journal.pone.0062547. Print 2013.

PMID:
23658742
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mutant p53 attenuates the anti-tumorigenic activity of fibroblasts-secreted interferon beta.

Madar S, Harel E, Goldstein I, Stein Y, Kogan-Sakin I, Kamer I, Solomon H, Dekel E, Tal P, Goldfinger N, Friedlander G, Rotter V.

PLoS One. 2013 Apr 22;8(4):e61353. doi: 10.1371/journal.pone.0061353. Print 2013.

PMID:
23630584
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.

Molchadsky A, Ezra O, Amendola PG, Krantz D, Kogan-Sakin I, Buganim Y, Rivlin N, Goldfinger N, Folgiero V, Falcioni R, Sarig R, Rotter V.

Cell Death Differ. 2013 May;20(5):774-83. doi: 10.1038/cdd.2013.9. Epub 2013 Feb 15.

PMID:
23412343
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Environmental evaluation of waste treatment scenarios for the towns Khanty-Mansiysk and Surgut, Russia.

Kaazke J, Meneses M, Wilke BM, Rotter VS.

Waste Manag Res. 2013 Mar;31(3):315-26. doi: 10.1177/0734242X12473792. Epub 2013 Feb 4.

PMID:
23381971
[PubMed - indexed for MEDLINE]
18.

Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues.

Landan G, Cohen NM, Mukamel Z, Bar A, Molchadsky A, Brosh R, Horn-Saban S, Zalcenstein DA, Goldfinger N, Zundelevich A, Gal-Yam EN, Rotter V, Tanay A.

Nat Genet. 2012 Nov;44(11):1207-14. doi: 10.1038/ng.2442. Epub 2012 Oct 14.

PMID:
23064413
[PubMed - indexed for MEDLINE]
19.

Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.

Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, Rotter V.

Carcinogenesis. 2013 Jan;34(1):190-8. doi: 10.1093/carcin/bgs318. Epub 2012 Oct 10.

PMID:
23054612
[PubMed - indexed for MEDLINE]
Free Article
20.

p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition.

Brosh R, Assia-Alroy Y, Molchadsky A, Bornstein C, Dekel E, Madar S, Shetzer Y, Rivlin N, Goldfinger N, Sarig R, Rotter V.

Cell Death Differ. 2013 Feb;20(2):312-20. doi: 10.1038/cdd.2012.125. Epub 2012 Sep 21.

PMID:
22996684
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk